Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients

• Status: Recruiting
• Trial end date: 2020-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Diabetes Mellitus is the leading cause of end stage renal disease. As proven by many studies , controlling proteinuria can delay the progression to end stage renal disease.This work will study the effect of sodium glucose co transporter 2 inhibitor , a new antihyperglycemic drug , on proteinuria and to compare its effect with the effect of classic antiproteinuric drugs as angiotensin converting enzyme inhibitor , aspirin and statins.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nahla H Tohami
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Sodium-Glucose Transporter 2 Inhibitors

Criteria

Inclusion Criteria:

• adult patients with type 2 diabetes.

• controlled diabetes.

• patients with proteinuria

Exclusion Criteria:

• patients with proteinuria due to other disease.

• patients with HbA1c >8%.

• patients with uncontrolled hypertension.

• patients with chronic liver disease.

• patients with type 1 diabetes .

• patients already on the same drug ( dapagliflozine).

• patients with raised serum creatinine.